FENC Fennec Pharmaceuticals Inc

Price (delayed)

$6.57

Market cap

$179.51M

P/E Ratio

73

Dividend/share

N/A

EPS

$0.09

Enterprise value

$158.07M

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development of PEDMARK™ for the prevention of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK has received Orphan Drug Designation ...

Highlights
The equity has soared by 126% from the previous quarter and by 126% YoY
Fennec Pharmaceuticals's net income has soared by 123% from the previous quarter and by 115% YoY

Key stats

What are the main financial stats of FENC
Market
Shares outstanding
27.32M
Market cap
$179.51M
Enterprise value
$158.07M
Valuations
Price to earnings (P/E)
73
Price to book (P/B)
59.07
Price to sales (P/S)
3.95
EV/EBIT
21.42
EV/EBITDA
19.51
EV/Sales
3.52
Earnings
Revenue
$44.95M
EBIT
$7.38M
EBITDA
$8.1M
Free cash flow
$27.48M
Per share
EPS
$0.09
Free cash flow per share
$1.02
Book value per share
$0.11
Revenue per share
$1.66
TBVPS
$2.56
Balance sheet
Total assets
$69.19M
Total liabilities
$66.18M
Debt
$29.75M
Equity
$3.01M
Working capital
$58.34M
Liquidity
Debt to equity
9.87
Current ratio
6.93
Quick ratio
6.25
Net debt/EBITDA
-2.65
Margins
EBITDA margin
18%
Gross margin
96.2%
Net margin
8.3%
Operating margin
13.9%
Efficiency
Return on assets
11.2%
Return on equity
N/A
Return on invested capital
23.3%
Return on capital employed
12.4%
Return on sales
16.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FENC stock price

How has the Fennec Pharmaceuticals stock price performed over time
Intraday
2.82%
1 week
0.46%
1 month
2.34%
1 year
-19.88%
YTD
-41.44%
QTD
7.53%

Financial performance

How have Fennec Pharmaceuticals's revenue and profit performed over time
Revenue
$44.95M
Gross profit
$43.24M
Operating income
$6.24M
Net income
$3.75M
Gross margin
96.2%
Net margin
8.3%
The operating income has soared by 149% QoQ and by 126% YoY
Fennec Pharmaceuticals's net income has soared by 123% from the previous quarter and by 115% YoY
Fennec Pharmaceuticals's operating margin has soared by 123% from the previous quarter and by 102% YoY
The gross profit has soared by 116% from the previous quarter

Growth

What is Fennec Pharmaceuticals's growth rate over time

Valuation

What is Fennec Pharmaceuticals stock price valuation
P/E
73
P/B
59.07
P/S
3.95
EV/EBIT
21.42
EV/EBITDA
19.51
EV/Sales
3.52
The company's EPS has surged by 115% QoQ and by 109% YoY
The equity has soared by 126% from the previous quarter and by 126% YoY
FENC's revenue has soared by 112% from the previous quarter
The P/S is 78% lower than the last 4 quarters average of 17.9

Efficiency

How efficient is Fennec Pharmaceuticals business performance
The return on invested capital has surged by 157% since the previous quarter and by 121% year-on-year
The company's return on sales has surged by 128% QoQ and by 102% YoY
The return on assets has surged by 116% since the previous quarter and by 111% year-on-year

Dividends

What is FENC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FENC.

Financial health

How did Fennec Pharmaceuticals financials performed over time
The total assets is 4.6% more than the total liabilities
The total assets has soared by 158% from the previous quarter and by 158% YoY
The quick ratio has soared by 114% from the previous quarter and by 114% YoY
The equity has soared by 126% from the previous quarter and by 126% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.